The patient receiving mitoxantrone (Novantrone) for treatment
of secondary progressive multiple sclerosis (MS) is closely
monitored for
a) leukopenia and cardiac toxicity.
Mitoxantrone is an antineoplastic agent used primarily to treat
leukemia and lyphoma but is also used to treat secondary progressive
MS. Patients need to have laboratory tests ordered and the results
closely monitored due to the potential for leukopenia and cardiac
toxicity.
b) mood changes and fluid and electrolyte alterations.
Patients receiving corticosteroids are monitored for side effects related
to corticosteroids such as mood changes and fluid and electrolyte
alterations.
c) renal insufficiency.
Patients receiving mitoxantrone are closely monitored for leukopenia
and cardiac toxicity.
d) hypoxia.
Patients receiving mitoxantrone are closely monitored for leukopenia
and cardiac toxicity.
of secondary progressive multiple sclerosis (MS) is closely
monitored for
a) leukopenia and cardiac toxicity.
Mitoxantrone is an antineoplastic agent used primarily to treat
leukemia and lyphoma but is also used to treat secondary progressive
MS. Patients need to have laboratory tests ordered and the results
closely monitored due to the potential for leukopenia and cardiac
toxicity.
b) mood changes and fluid and electrolyte alterations.
Patients receiving corticosteroids are monitored for side effects related
to corticosteroids such as mood changes and fluid and electrolyte
alterations.
c) renal insufficiency.
Patients receiving mitoxantrone are closely monitored for leukopenia
and cardiac toxicity.
d) hypoxia.
Patients receiving mitoxantrone are closely monitored for leukopenia
and cardiac toxicity.